A common challenge in the field of regenerative science is the variability found in "bedside" applications. When biological materials are taken from a patient's own body—a process known as an autologous application—the quality may vary greatly depending on their age and health. To address this, many are looking toward the Regenerative Protein Array (RPA) by Genesis Regenerative, which offers a standardized, lab-controlled alternative. This non-cellular approach featuring more than 300 proteins has shown promise in providing a more consistent way to support tissue health.
When a biological application relies on a patient’s own cells, the results are often difficult to predict because the starting material is inconsistent. For example, a younger patient might have a high concentration of growth factors, while an older patient or someone with chronic health concerns may have a significantly lower count. This makes it difficult for clinicians to know exactly what dose of signaling molecules the patient is receivin
